What's New


April 28, 2016-Swiss Broadcasting Corporation - Colombian minister proposes ending Novartis patent

April 26, 2016 - Fort Erie Times: Niagara company offers U.S. cheaper cancer drug

April 26, 2016 - The Inter-American Dialogue's daily Latin American Advisor -- Q&A with Public Citizen's Peter Maybarduk

April 12, 2016 - Common Dreams: Think Medicine is Expensive Now? Public Health Groups Warn of TPP's Gifts to Big Pharma

April 12, 2016 - NGO Letter to Congress Calling for Rejection of TPP Due to Concerns over Public Health Impacts

April 12, 2016 - Washington Post: More than 50 health, religious and labor groups urge Congress to reject TPP trade deal

For older news, visit the Access to Medicines news archive

U.S. Pressure Against Countries' Public Interest Policies


Global Access to Medicines Program Director Peter Maybarduk delivers testimony at USTR's 2014 Special 301 hearing.

Public Citizen Statement on the 2014 Special 301 Report


April 30, 2014

U.S. Chamber, Big Pharma Miss Their Target on India Trade, But U.S. Watch List Still Bullies India, Other Developing Countries Over Health Policies

Statement of Peter Maybarduk, Director, Public Citizen Global Access to Medicines Program

Note: Today, the Office of the U.S. Trade Representative (USTR) released its annual Special 301 Report. The 301 Report places countries on a watch list for practices the U.S. government believes reflect “inadequate” intellectual property (IP) protection, even when these policies safeguard important public interests including health.

The Special 301 Report's watch list is a morally repugnant and unnecessary U.S. government practice, which annually bullies countries for implementing polices that promote access to lifesaving medicines despite serious questions about the legality of such unilateral threats under international law. The 301 watch list should be discontinued in its entirety. Continue reading...

Resources

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.